SCHEMBL6624494

SCHEMBL6624494

O=C(Cc1sccc1NS(=O)(=O)c1ccc(-c2ccc3c(c2)OCO3)cc1)N1CCOCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.46
FKBP1A P62942 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
HPGD P15428 2/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
RAB9A P51151 1/20 0.43
LMNA P02545 5/20 0.41
ALDH1A1 P00352 1/20 0.41
TSHR P16473 1/20 0.40
GAA P10253 1/20 0.40
CA12 O43570 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP3 P08254 1/20 0.39
MMP13 P45452 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6623416 0.86 MAPT (0.53) L3MBTL1SMN1; SMN2RAB9ALMNAALDH1A1
SCHEMBL6624371 0.85 KMT2A (0.48) NPC1RAB9ALMNAALDH1A1GAA
SCHEMBL6695816 0.85 LMNA (0.45) L3MBTL1FKBP1ATP53LMNAALDH1A1
SCHEMBL6625889 0.85 L3MBTL1 (0.46) L3MBTL1FKBP1ASMN1; SMN2HPGDNPC1
SCHEMBL6626083 0.84 ALDH1A1 (0.41) L3MBTL1LMNAALDH1A1TSHRGAA
SCHEMBL6628476 0.83 ALDH1A1 (0.41) L3MBTL1SMN1; SMN2LMNAALDH1A1TSHR
SCHEMBL6623605 0.83 ALDH1A1 (0.55) L3MBTL1SMN1; SMN2HPGDTP53LMNA
SCHEMBL6628164 0.82 RAB9A (0.44) HPGDNPC1RAB9ALMNAALDH1A1
SCHEMBL6697053 0.82 KMT2A (0.47) SMN1; SMN2HPGDLMNAALDH1A1GAA
SCHEMBL7081696 0.82 CYP2C9 (0.52) SMN1; SMN2NPC1RAB9ALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO claimed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO disclosed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 L3MBTL1 4282/4885FKBP1A 466/4885SMN1; SMN2 3179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.